ALSO NOTED: Vital Therapies raises venture funds; HemoSense raising $10M; GTC Biotherapeutics inks development deal; and much m

> Vital Therapies has raised $8 million in a new round of venture capital. Report

> San Jose, CA-based HemoSense is raising $10 million in a private placement. Release

> GTC Biotherapeutics of Framingham, MA, and Denmark's LEO Parma have inked a deal to jointly develop Atryn, GTC's recombinant form of human antithrombin with $73 million in potential milestone payments. Report

> Analysts are expecting Eyetech's Macugen to lose market share to Genetech's Lucentis. Report

> Bristol, TN-based King Pharmaceuticals has agreed to pay $124 million to resolve claims that it overcharged Medicaid and Medicare for drugs over the past nine years. Article

> Novavax has raised $18 million from a private offering of 4.1 million shares. Release

> NicOx has extended its collaboration agreement with Merck. Release

> Canada's Caprion Pharmaceuticals will collaborate with AstraZeneca focused on the discovery of novel targets for the treatment of prostate cancer. Release

> VaxGen plans to catch up on releasing its financial reports in the first quarter of next year. Report

And Finally... Physicians at the AMA are considering how doctors should handle patients in the event of a quarantine triggered by an avian flu pandemic. Article